RCT: COVID outpatients don’t benefit from hydroxychloroquine, lopinavir-ritonavir

COVID outpatients don’t benefit from hydroxychloroquine, lopinavir-ritonavir – CIDRAP

Original study: Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial – JAMA Network Open

Commentary on Twitter (thread – Click for more)

1/ No benefit from Hydroxychloroquine or Lopinavir-Ritonavir on Hospitalization/Viral clearance for COVID-19 https://t.co/yhXxv26418 via @JAMANetworkOpen part of @JAMANetwork

— Priya Sampathkumar (@PSampathkumarMD) April 22, 2021